150 related articles for article (PubMed ID: 16718300)
1. New Zealand cancer patients should have access to erythropoietin treatment.
Carter J; Clay J
N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
[TBL] [Abstract][Full Text] [Related]
2. PHARMAC and erythropoietin for cancer patients.
Grocott R; Metcalfe S; Moodie P
N Z Med J; 2006 Jun; 119(1236):U2039. PubMed ID: 16807581
[No Abstract] [Full Text] [Related]
3. [Health policy decisions between rationing and rationalization--exemplified by erythropoietin in tumor anemia].
Wild C; Jonas S
Gesundheitswesen; 2001 Apr; 63(4):221-5. PubMed ID: 11367951
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer.
Dempke W
Anticancer Res; 2007; 27(4A):1745-57. PubMed ID: 17649769
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin: can we afford to use it? Can we afford not to?
Laird J
Transfus Med; 2006 Jun; 16(3):204-5. PubMed ID: 16764600
[TBL] [Abstract][Full Text] [Related]
6. Anemia therapy: individual benefit and societal cost.
Denton TA; Diamond GA; Matloff JM; Gray RJ
Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
[TBL] [Abstract][Full Text] [Related]
7. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
Repetto L; Moeremans K; Annemans L;
Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of recombinant erythropoietin in anemic cancer patients.
Henry DH
Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-stimulating agents in oncology.
Savona MR; Silver SM
Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand.
Bell D; Grimes D; Gurney H; Dalley D; Blackwell T; Fox R; Jeffery M
Intern Med J; 2008 Oct; 38(10):751-7. PubMed ID: 19143877
[TBL] [Abstract][Full Text] [Related]
11. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
McNaughton H; Kayes N; McPherson K
N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
[TBL] [Abstract][Full Text] [Related]
12. The ASH/ASCO clinical guidelines on the use of erythropoietin.
Lichtin A
Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
[TBL] [Abstract][Full Text] [Related]
13. [Concern about the safety of erythropoietin in cancer patients].
van der Lelie J
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):920-2. PubMed ID: 18561786
[TBL] [Abstract][Full Text] [Related]
14. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
15. New EORTC guidelines for the treatment of anaemia in patients with cancer: implications for nursing practice.
Foubert J
Eur J Oncol Nurs; 2006 Jul; 10(3):177-86. PubMed ID: 16199202
[TBL] [Abstract][Full Text] [Related]
16. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
17. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Grocott R; Metcalfe S
N Z Med J; 2005 Oct; 118(1223):U1690. PubMed ID: 16224510
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
19. Anaphylaxis management: the essential role of adrenaline (epinephrine) auto-injectors. Should PHARMAC fund them in New Zealand?
Fitzharris P; Empson M; Ameratunga R; Sinclair J; Crump V; Steele R; Broom B
N Z Med J; 2006 May; 119(1233):U1965. PubMed ID: 16680178
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.
Chapko MK; Dominitz JA
Aliment Pharmacol Ther; 2006 Oct; 24(7):1067-77. PubMed ID: 16984501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
